CGEN
Compugen Ltd

2,553
Mkt Cap
$160.88M
Volume
1,578.00
52W High
$2.66
52W Low
$1.13
PE Ratio
-5.75
CGEN Fundamentals
Price
$1.73
Prev Close
$1.72
Open
$1.72
50D MA
$1.63
Beta
1.65
Avg. Volume
586,136.09
EPS (Annual)
-$0.159
P/B
3.67
Rev/Employee
$376,540.54
Loading...
Loading...
News
all
press releases
Compugen (NASDAQ:CGEN) Issues Quarterly Earnings Results
Compugen (NASDAQ:CGEN - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of +22.22% and -14.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
Certara (CERT) delivered earnings and revenue surprises of +27.27% and -0.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Compugen to Participate in Stifel 2025 Healthcare Conference
Compugen to Participate in Stifel 2025 Healthcare Conference Compugen to Participate in Stifel 2025 Healthcare Conference PR Newswire HOLON, Israel, Nov. 4, 2025 HOLON, Israel, Nov. 4, 2025...
PR Newswire·8d ago
News Placeholder
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 PR Newswire HOLON, Israel, Oct. 27, 2025 HOLON...
PR Newswire·16d ago
News Placeholder
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 Compugen to Present Pooled Analysis of COM701 in Three Phase 1...
PR Newswire·1mo ago
News Placeholder
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·5mo ago
News Placeholder
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·5mo ago

Latest CGEN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.